Oncolys BioPharma develops breakthrough therapy and diagnostics in cancer treatment from early to late stage.
Business Model:
Revenue: $7.1M
Employees: 11-50
Address:
City: Tokyo
State: Tokyo
Zip:
Country: Japan
Oncolys BioPharma Inc. is a biopharmaceutical company. The Company operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The Company&s;s main pipeline includes OBP-601 for the treatment of human immunodeficiency virus (HIV) infection; OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug; OBP-1101 (Telomescan F35), a virus for blood floating cancer cells (CTC) detection; OBP-401 (Telomescan), a virus for inflammatory disease detection, and OBP-1102, a virus for leukemia detection, among others.
Contact Phone:
Contact Email:
Listed Exchange:
Tokyo Stock Exchange
IPO Date:
12/6/2013
Ticker Symbol:
4588
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2017 | Precision Virologics | Seed Round | 0 |
2/2018 | Unleash Immuno Oncolytics | Equity | 3M |
2/2018 | Unleash Immuno Oncolytics | Venture Round | 0 |
3/2017 | Precision Virologics | Seed Round | 0 |
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|